

O I P E  
JC54  
Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SEP 24 2002

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of 3

### Complete If Known

Application Number	09/505,788
Filing Date	February 17, 2000
First Named Inventor	Olson
Group Art Unit	1624
Examiner Name	B. Coleman

Attorney Docket Number PH-7076-A

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	class	Subclass
		Number	Kind Code <sup>2</sup> (if known)					
BC		4929614		Calvet et al	5/29/1990	514	214	
BC		5283241		Bochis et al	2/1/1994	514	183	
BC		5550126		Horwell et al	8/27/1996	514	237.5	
BC		5532359		Marsters et al	7/2/1996	540	522	
BC		5578629		Ciccarone et al	11/26/1996	514	347	
BC		5595990		Baldwin et al	1/21/1997	514	221	
BC		5602145		Samanen	2/11/1997	514	309	
BC		5602156		Kohn et al	2/11/1997	514	359	
BC		5618812		Castro Pineiro et al	4/8/1997	514	221	
BC		5672596		Wyvrott et al	9/30/1997	514	183	
BC		5703129	Felsenstein	Ghatanvedula et al	12/30/1997	514	70	613
BC		5710153		Ohmoto et al	1/20/1998	514	236.2	
BC		5710171		Dinsmore et al	1/20/1998	514	301.6	
BC		5756528		Anthony et al	5/26/1998	514	301	
BC		5763437		Sato et al	6/9/1998	514	221	
BC		5770573		Arrhenius et al	6/23/1998	514	18	
BC		5852010		Graham et al	12/22/1998	514	221	
BC		5856326		Anthony et al	1/5/1999	514	221	
BC		5859012		Dinsmore et al	4/6/1999	514	359	
BC		5869682		DeSolms	2/9/1999	548	290	335.5
BC		5872135		DeSolms	2/16/1999	514	326	
BC		5885995		Dinsmore	3/23/1999	514	252	
BC		5891889		Anthony et al	4/6/1999	514	326	
BC		5905077		Jungheim et al	5/18/1999	514	222.2	
BC		5919785		Dinsmore et al	7/6/1999	514	255	
BC		5936089		Carpino et al	8/10/1999	546	143	
BC		5965578		Graham et al	10/12/1999	514	326	
BC		5985900	Blender	Abroo et al	11/16/1999	514	336	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
BC		WO	9828268		Athena Neurosciences Inc.	7/2/1998		
BC		WO	9822493		Athena Neurosciences Inc.	5/28/1998		
BC		WO	9822433		Athena Neurosciences Inc.	5/28/1998		
BC		WO	9822430		Athena Neurosciences Inc.	5/28/1998		
BC		WO	9822441		Athena Neurosciences Inc.	5/28/1998		

Examiner Signature

Brenda Coleman


Date Considered

Dec. 9, 2002 / March 12, 2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

TECH CENTER 1600/2900  
SEP 3 0 2002



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 3

### Complete If Known

Application Number	09/505,788
Filing Date	February 17, 2000
First Named Inventor	Olson
Group Art Unit	1624
Examiner Name	B. Coleman
Attorney Docket Number	PH-7076-A

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
BC		WO	9837079		Berlex Laboratories Inc.	8/27/1998		
BC		WO	9858915		Boehringer Mannheim GMBH	12/30/1998		
BC		WO	9918951		Bristol-Myers Squibb Co.	4/22/1999		
BC		WO	9903826		British Biotech Pharmaceuticals Ltd.	1/28/1999		
BC		WO	9719053		British Biotech Pharmaceuticals Ltd.	5/29/1997		
BC		WO	9633165		British Biotech Pharmaceuticals Ltd.	10/24/1996		
BC		WO	9712861		Chiro-Science Ltd.	4/19/1997		
BC		WO	9816523		COR Therapeutics Inc.	4/23/1998		
BC		WO	9907730		COR Therapeutics Inc.	2/18/1999		
BC		WO	9907731		COR Therapeutics Inc.	2/18/1999		
BC		WO	0002903		Cytel Corp.	1/20/2000		
BC		WO	0160826		DuPont Pharmaceuticals Co.	8/23/2001		
BC		WO	0038618		DuPont Pharmaceuticals Co.	7/6/2000		
BC		WO	0007995		DuPont Pharmaceuticals Co.	2/17/2000		
BC		WO	0028331		DuPont Pharmaceuticals Co.	5/18/2000		
BC		WO	9967221		Elan Pharmaceuticals Inc.	12/29/1999		
BC		WO	9967220		Elan Pharmaceuticals Inc.	12/29/1999		
BC		WO	9966934		Elan Pharmaceuticals Inc.	12/29/1999		
BC		WO	9967219		Elan Pharmaceuticals Inc.	12/29/1999		
BC		WO	9932453		Elan Pharmaceuticals Inc.	7/1/1999		
BC		EP	0842944		Hoechst Aktiengesellschaft	5/20/1998		
BC		WO	0848957		Kanebo Ltd.	6/24/1998		
BC		WO	9919305		Krenitsky Pharmaceuticals Inc.	4/22/1999		
BC		WO	9403437		Merck Sharp & Donue	2/17/1994		
BC		WO	9828980		Merck & Co. Inc.	7/9/1998		
BC		EP	0434360		Merck & Co. Inc.	6/26/1991		
BC		EP	0421802		Merck & Co. Inc.	4/10/1991		
BC		WO	9736877		Merck & Co. Inc.	10/9/1997		
BC		WO	9509633		Merck & Co. Inc.	4/13/1995		
BC		WO	9736879		Merck & Co. Inc.	10/9/1997		
BC		WO	9917777		Merck & Co. Inc.	4/15/1999		
BC		WO	9405634		Merck & Co. Inc.	3/17/1994		
BC		WO	9639137		Merck & Co. Inc.	12/12/1996		
BC		WO	9844797		Merck & Co. Inc.	10/15/1998		
BC		WO	9745412		Merck & Co. Inc.	12/4/1997		

Examiner Signature

Brenda Coleman

Date Considered

Dec. 9, 2002 / March 12, 2004

EAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number.<sup>2</sup> See attached Kinds of U.S. Patent Documents.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

TECH CENTER 1600/2900  
SEP 30 2002

Institute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

**Complete If Known**

Application Number	09/505,788
Filing Date	February 17, 2000
First Named Inventor	Olson
Group Art Unit	1624
Examiner Name	B. Coleman
Attorney Docket Number	PH-7076-A

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
BC		WO	9727852		Merck & Co. Inc.	8/7/1997		
BC		WO	9900654		Merck & Co. Inc.	1/7/1999		
BC		WO	9745412		Merck & Co. Inc.	12/4/1997		
BC		WO	9738664		Merck & Co. Inc.	10/23/1997		
BC		WO	9736900		Merck & Co. Inc.	10/9/1997		
** BC		WO	9827053		Ono Pharmaceutical Co.	6/25/1998		
		WO	9942880		Pfizer Products Inc.	2/11/1997		
BC		WO	9620918		Procter & Gamble Co.	7/11/1996		
BC		WO	9629313		Procter & Gamble Co.	9/26/1996		
** BC		WO	9835941		Shionogi & Co. Inc.	8/20/1998		
** BC		WO	9841510		Shionogi & Co. Inc.	9/24/1998		
BC		WO	9217460		Smithkline Beecham Corp.	10/15/1992		
BC		WO	9414776		Smithkline Beecham Corp.	7/7/1994		
BC		WO	9618602		Smithkline Beecham Corp.	6/20/1996		
BC		WO	9617833		Smithkline Beecham Corp.	6/13/1996		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BC		Dingwall; J. Clinical Invest., 108, Nov. 2001, 1243-1246	
BC		Selkoe; J. Alzheimer's Disease, 3, 2001, p. 75-81	
		Tanzi and Pareen, "Decoding Darkness, The Search for the Genetic Causes of Alzheimer's Disease", Perseus Publishing, 2000, pages xvii-xviii	
BC		Olson et al., Current Opinion in Drug Discovery and Development, 4, 2001, p. 390-401	
BC		Su San Mok et al, A Novel Metalloprotease in Rat brain cleaves..Biochemistry, vol. 36, no 1, 1997, pages 156-63 XP002177252	
BC		Database WPI, Section Ch, Week 199839, Derwent Pub. Ltd., London GB; Class B02, AN 1998-457046 XP002203452, 1998	
BC		Patani et al, Bioisosterism: A Rational Approach in Drug Design, Chem. Rev., 1996, 96, 3147-3176 XP000652176	
BC		Natchus et al, Design and Synthesis of Conformationally-Constrained MMP Inhibitors, Bioorganic & Medicinal Chem. Letters 8 (1998) 2077-2080 XP004137222	
BC		Yong et al, Matrix Metalloproteinases and Diseases of the CNS, TINS Vol. 21, No. 2, 1998 75-80 XP000942162	

Examiner Signature	Brenda Coleman	Date Considered	Dec. 9, 2002/Marcel
--------------------	----------------	-----------------	---------------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

\*\* structures only

12, 2004